Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology.
Peter Robert GalleMasatoshi KudoJosep M LlovetRichard S FinnMark KarwalDenis PezetTae-You KimTsai-Sheng YangSara LonardiJiri TomasekJean-Marc PhelipYann TouchefeuSu-Jin KohGuido StirnimannKun LiangKenyon D OgburnChunxiao WangPaolo AbadaRyan C WidauAndrew X ZhuPublished in: Liver international : official journal of the International Association for the Study of the Liver (2021)
Ramucirumab improved survival across aetiology subgroups with a tolerable safety profile, supporting its use in patients with aHCC and elevated AFP.
Keyphrases